SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-004134
Filing Date
2017-05-10
Accepted
2017-05-10 16:31:38
Documents
66
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20170331x10q.htm 10-Q 1096012
2 EX-31.1 gemp-20170331ex311277502.htm EX-31.1 17551
3 EX-31.2 gemp-20170331ex312cfe6b7.htm EX-31.2 17666
4 EX-32.1 gemp-20170331ex321e70361.htm EX-32.1 12001
  Complete submission text file 0001558370-17-004134.txt   4307666

Data Files

Seq Description Document Type Size
5 EX-101.INS gemp-20170331.xml EX-101.INS 608226
6 EX-101.SCH gemp-20170331.xsd EX-101.SCH 47092
7 EX-101.CAL gemp-20170331_cal.xml EX-101.CAL 27957
8 EX-101.DEF gemp-20170331_def.xml EX-101.DEF 181241
9 EX-101.LAB gemp-20170331_lab.xml EX-101.LAB 395384
10 EX-101.PRE gemp-20170331_pre.xml EX-101.PRE 322015
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 17830780
SIC: 2834 Pharmaceutical Preparations